VacZine Analytics  
MarketVIEW: hepatitis A vaccines (Emerging/ROW)

Published: July 2012

Hepatitis A (HAV) produces a self-limiting liver disease which can produce a range of symptoms such as nausea, anorexia, fever, malaise or abdominal pain. Unlike Hepatitis B and C viruses it does not cause a long term chronic infection although it can manifest itself as prolonged or relapsing disease for up to six months. The HAV virus is transmitted by person-to-person transmission through the fecal-oral route sometimes in outbreaks to due ingestion of contaminated food. Many countries in Africa, LATAM and SE Asia have high or intermediate endemnicity for HAV.

The Hepatitis A vaccine is highly effective at preventing HAV infection and is now recommended for all children at age 1 year in the United States and other selected countries which have added the vaccine as part of a national immunization program (NIP). The HAV vaccine is also widely used in the travelling population to high or intermediate endemic countries.

This MarketVIEW product is a comprehensive commercial opportunity assessment which forecasts the potential (value/volume) of HAV vaccines in 35 countries in the "Emerging" or Rest of World region (ROW) to 2030. The model takes into account expected new NIPs, probable "catch-up" campaigns and expansion of private sector use in selected age groups. A detailed executive presentation is also included outlining all model outputs, assumptions and a country-by-country review of epidemiological dynamics and vaccination policy.


To order please contact your region account manager, buy "on-line" or order direct at:

VAMV029 Click here>>
Discounted option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?

© 2011 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains